Ostéoporose cortisonique

Revue du Rhumatisme (Edition Francaise)

Volumn 68, Issue 8, 2001, Pages 678-684

  Orcel, Philippe ^a   Roux, Christian ^b  

^a CENTRE VIGGO PETERSEN   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

Bisphosphonate; Glucocorticoids; Glucocortico des; Osteoblast; Osteodensitometry; Osteoporosis; Ost oblastes; Ost odensitom trie; Ost oporose; Ost oporose secondaire bisphosphonate; Secondary osteoporosis

Indexed keywords

EID: 18044400207     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(01)00181-8     Document Type: Short Survey

References (42)

1. 1 Orcel P, Beaudreuil J. Ostéoporose cortisonique. Encyd Méd Chir, Appareil Locomoteur, Eisevier, Paris, 14-025-C-1 0, 2000, 4p.
2. 2 Walsh LI, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis : a cross sectional study. Br Med J 1996 ; 313 : 344-6.
3. 3 Van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 2000 ; 93 : 105-11.
4. 4 Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis : an opportunity for prevention ? Ann Rheum Dis 1995 ; 54 : 66-8.
5. 5 Buckley LM, Marquez M, Hudson JO, Downs RW, Vacek P, Small RE, et al. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 1998 ; 25 : 2195-202.
6. 6 Soucy E, Bellamy N, Adachi JD, Pope JE, Flynn J, Sutton E, et al. A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. J Rheumatol 2000 ; 27 : 1506-12.
7. 7 Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000 ; 15 : 993-1000.
8. 8 Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk : relationship to daily and cumulative doses. Rheumatology 2000 ; 39 : 1383-9.
9. 9 Cohen Solal M, Orcel B, Orcel P. Retentissement osseux des glucocorticoïdes inhalés. In : Kahn MF, Kuntz D, Meyer O, Bardin T, Orcel P, Eds. L'Actualité rhumatologique. Paris : Elsevier ; 2000. p. 261-71.
10. 10 Van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001 ; 16 : 581-8.
11. 11 Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis M, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis : an update. J Intern Med 1998 ; 244 : 271-92.
12. 12 Orcel P. Ostéoporose cortisonique : nouvelles approches. Rev Rhum [Éd Fr] 1997 ; 64 : 717-26.
13. 13 Canahs E. Mechanisms of glucocorticoid action in bone : implications to glucocorticoid-induced osteoporosis. J Endocrinol Metab 1996 ; 81 : 3441-7.
14. 14 Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999 ; 14 : 1061-6.
15. 15 Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998 ; 102 : 274-82.
16. 16 Manolagas SC. Corticosteroids and fractures : a close encounter of the third cell kind. J Bone Miner Res 2000 ; 15 : 1001-5.
17. 17 Roux S, Orcel P. Bone loss. Factors that regulate osteoclast differentiation : an update. Arthritis Res 2000 ; 2 : 451-6.
18. 18 Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells : potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 ; 140 : 4382-9.
19. 19 Chappard D, Legrand E, Baslé MF, Fromont P, Racineux JL, Rebel A, et al. Altered trabecular architecture induced by corticosteroids : a bone histomorphometry study. J Bone Miner Res 1996 ; 11 : 676-85.
20. 20 Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001 ; 16 : 97-103.
21. 21 Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000 ; 2 : CD000952.
22. 22 Hall GMI, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994 ; 37 : 1499-505.
23. 23 Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwer P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000 ; 2 : CD000952.
24. 24 Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, et al. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis : a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000 ; 15 : 754-62.
25. 25 Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999 ; 104 : 1363-74.
26. 26 Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997 ; 337 : 382-7.
27. 27 Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998 ; 83 : 1128-33.
28. 28 Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MID. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999 ; 28 : 152-6.
29. 29 Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid-induced bone loss. J Rheumatol 2000 ; 27 : 2424-31.
30. 30 Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Coemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1999 ; 339 : 292-9.
31. 31 Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids : a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001 ; 44 : 202-11.
32. 32 Cohen S, Levy M, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss : a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999 ; 42 : 2309-18.
33. 33 Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women : a randomized trial. European Corticosteroid-induced Osteoporosis Treatment Study. J Bone Miner Res 2000 ; 15: 1006-13.
34. 34 Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000 ; 11 : 331-7.
35. 35 Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi ID, et al. A metaanalysis on the use of bisphosphonates in corticosteroid-induced osteoporosis. J Rheumatol 1999 ; 26 : 1148-57.
36. 36 Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 2000 ; 2 : CD001347.
37. 37 Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000 ; 67 : 277-85.
38. 38 Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium : a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001 ; 16 : 104-12.
39. 39 American College of Rheumatology Task Force on Osteoporosis guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996 ; 39 : 1791-801.
40. 40 Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000 ; 29 : 228-51.
41. 41 Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999 ; 104 : 439-46.
42. 42 Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998 ; 102 : 1627-33.